glp1check.in

Wondering if semaglutide is right for you? Get a clinically grounded answer in 5 minutes — free, anonymous, built for India.

[glp1check.in @glp1check]

If you've:
• Tried 3+ structured diets, no movement
• Been told you're "not big enough" for medication
• Researched semaglutide privately
• Got a vague answer from your GP

The 5-min assessment is for you. Indian guidelines. No upsell.

https://t.co/pLRAF7Muho
#DiabetesIndia

[glp1check.in @glp1check]

STEP 5 trial: 84% of prediabetic patients on semaglutide returned to normal blood sugar at 2 years.

13.6 crore Indians are prediabetic right now. Most don't know they qualify for treatment.

Fasting glucose 100–125? You.

https://t.co/pLRAF7Muho

#PreDiabetes #DiabetesIndia

[glp1check.in @glp1check]

If your GP's first answer to type 2 diabetes is metformin + "try harder", that's 2010 medicine.

@Rssdi_official now lists semaglutide as first-line for T2D with obesity. Same as the ADA.

The conversation has moved on. Has yours?

https://t.co/pLRAF7Muho

#DiabetesIndia

[glp1check.in @glp1check]

Indian men: waist > 90cm = abdominal obesity. BMI doesn't matter.
Indian women: > 80cm = same.

~1 in 3 "normal-weight" Indian adults crosses the line. Visceral fat is what GLP-1 acts on — the scale lies.

Pulled out a measuring tape recently?

#MetabolicHealth

[glp1check.in @glp1check]

Semaglutide is Schedule-H — prescription only.

@IndiaToday: GLP-1s sold OTC in Delhi. Hospitalisations followed. https://t.co/WJ9HJ6ynLe

Get assessed. Then see a doctor.

#PatientSafety

[glp1check.in @glp1check]

Ozempic. Wegovy. Rybelsus. Same molecule: semaglutide. Mounjaro is different — that's tirzepatide, a GLP-1/GIP dual.

Ozempic → T2D injection
Wegovy → weight injection
Rybelsus → oral tablet

Your indication picks the drug. Not the other way around.

#GLP1

[glp1check.in @glp1check]

A year ago, semaglutide cost ₹10,850/month in India. Half a median Delhi household's monthly income.

Generic launched. Brands now start at ₹1,290.

Same drug. Different economics. Different question of who gets it.

https://t.co/pLRAF7Muho

#SemaglutideIndia

[glp1check.in @glp1check]

"Will Ozempic make me vomit?"

Most-asked question on our assessment. Honest answer: nausea is real but fades in 2–4 weeks for most. Appetite suppression is the dominant, lasting effect — that's how the drug works.

Anyone here found dose-pacing helped?

#SemaglutideIndia

[glp1check.in @glp1check]

Your BMI is 24. Doctor said you're fine.

@ICMRDELHI says you're overweight.

The Indian BMI cutoff is 23 — not 25. South Asian fat distribution makes the Western threshold clinically wrong for us.

What's your number?

https://t.co/pLRAF7Muho

#DiabetesIndia #MetabolicHealth

[glp1check.in @glp1check]

Quick fact: waist circumference matters as much as weight for GLP-1 eligibility in Indians. The Indian cut-off is 90cm for men and 80cm for women. Most people don't know their number.

[glp1check.in @glp1check]

The STEP 5 trial found semaglutide restored normal blood sugar in 84–89% of prediabetic patients. 136 million Indians are currently in the prediabetes range. https://t.co/pLRAF7Muho

[glp1check.in @glp1check]

Before generic semaglutide, the monthly cost in India was ₹10,850–16,400. It's now available from ₹1,290. That's a meaningful change in who can access this treatment.

[glp1check.in @glp1check]

101.3 million Indians live with type 2 diabetes. Semaglutide is now considered first-line pharmacotherapy for T2D with obesity by Indian endocrinology guidelines. https://t.co/pLRAF7Muho

[glp1check.in @glp1check]

Semaglutide is a Schedule-H prescription drug in India. It's not available OTC, and it shouldn't be. But understanding if you're a candidate before seeing a doctor is a reasonable first step. https://t.co/pLRAF7Muho

[glp1check.in @glp1check]

The STEP 1 trial showed an average weight loss of 14.9% over 68 weeks. That's not a small number. But it also requires medical supervision, the right dose, and lifestyle changes alongside it.

[glp1check.in @glp1check]

Semaglutide brands now available in India: Noveltreat (Sun Pharma), Obeda (Dr Reddy's), Semaglyn (Zydus), SUNDAE (Eris/Natco), Samakind (Mankind). We track them all at https://t.co/NROsadJtTV

[glp1check.in @glp1check]

PCOS affects roughly 1 in 5 Indian women. Insulin resistance is the shared mechanism with obesity. GLP-1 therapy addresses both. Worth knowing if it's relevant to you → https://t.co/NJHTj3nxqL

[glp1check.in @glp1check]

43% of Indians are metabolically obese despite having a "normal" BMI by Western standards. This is the thin-fat Indian phenotype — well documented, rarely discussed outside clinical settings. https://t.co/pLRAF7Muho

[glp1check.in @glp1check]

A lot of people are Googling semaglutide right now and getting information written for a US or UK audience. We built something specifically for India. https://t.co/pLRAF7Muho

[glp1check.in @glp1check]

The SELECT trial found semaglutide reduced heart attacks and strokes by 20% in people with obesity and heart disease. That's a meaningful number for a country with India's cardiovascular burden. https://t.co/pLRAF7Muho